Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ambrx has entered into a global, strategic collaboration with Merck & Co. to develop a novel therapeutic protein with biological properties similar to fibroblast growth factor 21, or FGF-2, for the treatment of type II diabetes and related metabolic disorders such as obesity.
Subscribe to our email newsletter
The transaction includes an initial upfront payment in addition to committed R&D payments. Ambrx will also be eligible to receive future milestone payments associated with research, development and commercialization of a drug candidate resulting from the collaboration along with royalties on net sales. Ambrx also has the right to exercise an ‘end of Phase II’ profit-sharing option. Additional terms of the agreement were not disclosed.
Stephen Kaldor, Ambrx’s president and CEO, said: “We are pleased to enter into this agreement with Merck, a world leader in the metabolic diseases field with a proven track record in the rapid development and launch of diabetes medicines. We are excited about the potential of our initial FGF-21 protein drug candidates, as they promise unique pharmacological efficacy in the treatment of diabetes, a disease of large and rapidly increasing prevalence.”